| |
Newsroom /
Health and Fitness
/
Health and Fitness
/
Acute Myeloid Leukemia (AML) - Pipeline Assessment and Market Forecasts to 2017
Acute Myeloid Leukemia (AML) - Pipeline Assessment and Market Forecasts to 2017
The AML Therapeutics Market is Forecast to Show Increased Growth until 2017
Hyderabad,
AP,
India
(prbd.net)
21/10/2010
GlobalData estimated the global Acute Myeloid Leukemia (AML) therapeutics market to be worth $174m in 2009. It is expected to grow to $279m with a Compound Annual Growth Rate (CAGR) of 6.1% by 2017. This growth is primarily attributed to the increase in the prevalence due to the increasing elderly population and the presence of a strong pipeline with many emerging therapies. Pfizer and Genzyme are the market leaders within the global AML therapeutics market. There is a high level of unmet need in the current AML market in terms of both safety and efficacy
The prevalence rate for AML globally was found to be 0.1% or 827,671 people. AML is a cancerous condition primarily associated with the elderly. The onset of the condition mostly occurs between the ages of 50 and 65. The yearly incidence of new AML diagnoses in the US is 17.6/100,000 for people 65 years of age or older, compared to 1.8/100,000 for people <65 years. The incidence of AML increases with age. A significant increase in AML incidence has occurred over the past 10 years, especially in the elderly population. From the above data it is clear that the greater number of AML patients seeking treatment in the next five to ten years will result in increased usage of therapeutics drugs which in turn will drive the AML therapeutics market.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Acute-Myeloid-Leukemia-AML-Pipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare
Combinational therapies employing anthracycline antibiotics (such as Idarubicin) were the most preferred treatment option for patients with primary AML. Mylotarg, which was identified as one of the most promising drugs for treating patients with relapsed AML, will be withdrawn from the market with effect from October 15, 2010 due to safety issues. Most R&D has been carried out in developing therapeutics that denature or alter DNA structure, thereby interfering with cancerous cell multiplication. The treatment options for AML are limited due to the presence of serious side effects linked to the current therapeutic options. This condition primarily affects persons above 65 years. With the current standard treatment options available for AML, older patients with AML continue to have inferior treatment outcomes including high treatment-related mortality and fewer and shorter remissions.This is because with old age the tolerability and responsiveness towards the drugs reduces and the comorbidity increases because of other old age related ailments. Hence the pharmaceutical manufacturers have been under immense pressure to develop effective options for the treatment of AML.
GlobalData, an industry analysis specialist, has released its new report, “Acute Myeloid Leukemia (AML) - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global AML therapeutics market. The report identifies the key trends shaping and driving the global AML therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global AML therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Acute-Myeloid-Leukemia-AML-Pipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare
Visit our report store: http://www.globaldata.com
For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|